Viveve Medical produces console systems used to treat vaginal laxity. In late May the company entered a new term loan for an initial $20 million that could increase to $30 million if certain conditions are met. Approximately $10.8 million of the initial borrowings was used to repay a legacy loan, and remaining proceeds are expected to support growth initiatives such as further build-out of the U.S. sales force. Pro forma for net proceeds, the company’s cash balance would be almost $41 million, which Zacks analyst Brian Marckx said equals about 20 months of operating capital at the current EBITDA burn rate. Marckx and the report indicate that this runway should provide more than enough capital to initiate and potentially complete the U.S.-based VIVEVE II clinical study to support a sexual function indication.

Total raised

$31M

Funding rounds

3

Latest round

Debt Financing

Latest activity

Aug 2017